Published in Proc Natl Acad Sci U S A on November 18, 2013
A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev Drug Discov (2015) 1.31
Synthetic Nanoparticles for Vaccines and Immunotherapy. Chem Rev (2015) 1.10
Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J Clin Invest (2015) 1.03
In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat Biotechnol (2015) 0.98
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines (Basel) (2015) 0.91
Immunomodulatory spherical nucleic acids. Proc Natl Acad Sci U S A (2015) 0.90
Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother (2015) 0.89
Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89
Supramolecular peptide vaccines: tuning adaptive immunity. Curr Opin Immunol (2015) 0.88
Beyond antigens and adjuvants: formulating future vaccines. J Clin Invest (2016) 0.87
From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov (2015) 0.85
Biomaterials for enhancing anti-cancer immunity. Curr Opin Biotechnol (2016) 0.85
TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. Eur J Immunol (2015) 0.85
In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models. Small (2014) 0.83
Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators. Pharmaceutics (2016) 0.83
Improving the clinical impact of biomaterials in cancer immunotherapy. Oncotarget (2016) 0.83
Nanoparticle conjugation enhances the immunomodulatory effects of intranasally delivered CpG in house dust mite-allergic mice. Sci Rep (2015) 0.81
Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol (2016) 0.80
Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. Small (2015) 0.80
Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery. Curr Opin Chem Eng (2015) 0.80
Applications of nanomaterials as vaccine adjuvants. Hum Vaccin Immunother (2014) 0.79
Targeted Programming of the Lymph Node Environment Causes Evolution of Local and Systemic Immunity. Cell Mol Bioeng (2016) 0.78
Antigen delivery by lipid-enveloped PLGA microparticle vaccines mediated by in situ vesicle shedding. Biomacromolecules (2014) 0.78
Engineering New Approaches to Cancer Vaccines. Cancer Immunol Res (2015) 0.78
Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting. Vaccines (Basel) (2016) 0.76
Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine. Cell Discov (2017) 0.75
Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses. Vaccine (2016) 0.75
Vaccine Adjuvants in Fish Vaccines Make a Difference: Comparing Three Adjuvants (Montanide ISA763A Oil, CpG/Poly I:C Combo and VHSV Glycoprotein) Alone or in Combination Formulated with an Inactivated Whole Salmonid Alphavirus Antigen. Vaccines (Basel) (2014) 0.75
A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population. Oncotarget (2016) 0.75
Modifying the tumor microenvironment using nanoparticle therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.75
Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles. Nanomedicine (Lond) (2015) 0.75
Intracellular Cleavable CpG Oligodeoxynucleotide-Antigen Conjugate Enhances Anti-tumor Immunity. Mol Ther (2017) 0.75
Optimization, Production, and Characterization of a CpG-Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen. Bioconjug Chem (2016) 0.75
Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model. Biomaterials (2016) 0.75
A polyethylenimine-modified carboxyl-poly(styrene/acrylamide) copolymer nanosphere for co-delivering of CpG and TGF-β receptor I inhibitor with remarkable additive tumor regression effect against liver cancer in mice. Int J Nanomedicine (2016) 0.75
Adjuvant-Loaded Subcellular Vesicles Derived From Disrupted Cancer Cells for Cancer Vaccination. Small (2016) 0.75
Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus. Vaccines (Basel) (2016) 0.75
Characterization of Innate Responses Induced by PLGA Encapsulated- and Soluble TLR Ligands In Vitro and In Vivo in Chickens. PLoS One (2017) 0.75
Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses. PLoS One (2017) 0.75
TEMPORARY REMOVAL: Synthetic nanovaccines for immunotherapy. J Control Release (2017) 0.75
Biomaterials Strategies for Generating Therapeutic Immune Responses. Adv Drug Deliv Rev (2017) 0.75
Dual-linker gold nanoparticles as adjuvanting carriers for multivalent display of recombinant influenza hemagglutinin trimers and flagellin improve the immunological responses in vivo and in vitro. Int J Nanomedicine (2017) 0.75
T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol (2008) 11.65
CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol (2001) 9.19
Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol (2007) 3.75
Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol (2001) 3.64
Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol (2004) 2.48
Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev (2011) 2.09
Engineering nano- and microparticles to tune immunity. Adv Mater (2012) 1.75
CD8 T cells utilize TRAIL to control influenza virus infection. J Immunol (2008) 1.75
Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol (2004) 1.74
Division of labor, plasticity, and crosstalk between dendritic cell subsets. Curr Opin Immunol (2007) 1.70
Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem (2004) 1.61
Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med (2003) 1.59
Regulation of effector and memory T-cell functions by type I interferon. Immunology (2011) 1.58
CpG still rocks! Update on an accidental drug. Nucleic Acid Ther (2012) 1.55
Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A (2011) 1.39
Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine (2010) 1.37
Engineering approaches to immunotherapy. Sci Transl Med (2012) 1.36
Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol (2003) 1.26
Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol (2008) 1.21
CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood (2003) 1.19
Trafficking of B cell antigen in lymph nodes. Annu Rev Immunol (2011) 1.15
Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS One (2013) 1.12
The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis. J Immunol (2004) 1.11
Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity. Bioconjug Chem (2002) 1.11
Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci Transl Med (2013) 1.09
Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model. J Antimicrob Chemother (2002) 1.08
CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. Eur J Immunol (2005) 1.06
In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol Pharm (2009) 1.02
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Adv Drug Deliv Rev (2013) 1.02
Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy. Bioconjug Chem (2010) 1.00
Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine (2011) 0.98
Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective. Adv Healthc Mater (2012) 0.98
Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination. Front Immunol (2012) 0.96
Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing small molecules, peptides, and proteins. Bioconjug Chem (2010) 0.95
Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine (2007) 0.92
Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity. Bioconjug Chem (2010) 0.92
Materials based tumor immunotherapy vaccines. Curr Opin Immunol (2013) 0.92
Kinetic and mechanistic requirements for helping CD8 T cells. J Immunol (2008) 0.91
Maintenance and attrition of T-cell memory. Crit Rev Immunol (2003) 0.91
Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs. Int Immunol (2006) 0.86
Conjugation of lipid and CpG-containing oligonucleotide yields an efficient method for liposome incorporation. Bioconjug Chem (2011) 0.79
Stable assemblies of cationic bilayer fragments and CpG oligonucleotide with enhanced immunoadjuvant activity in vivo. J Control Release (2011) 0.79
Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol (2006) 8.81
Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol (2005) 4.59
Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol (2007) 3.75
Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat Biotechnol (2003) 3.71
Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst (2005) 3.58
Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science (2010) 3.08
Mechanobiology in the third dimension. Ann Biomed Eng (2005) 2.89
Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J (2003) 2.85
Interstitial flow as a guide for lymphangiogenesis. Circ Res (2003) 2.82
Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell (2007) 2.48
Materials engineering for immunomodulation. Nature (2009) 2.18
Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat Mater (2008) 2.12
Overexpression of VEGF-C causes transient lymphatic hyperplasia but not increased lymphangiogenesis in regenerating skin. Circ Res (2005) 2.08
Interstitial fluid flow induces myofibroblast differentiation and collagen alignment in vitro. J Cell Sci (2005) 2.07
In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release (2006) 2.05
Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ Res (2004) 1.97
Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol (2006) 1.85
Oxidation-responsive polymeric vesicles. Nat Mater (2004) 1.82
Controlling integrin specificity and stem cell differentiation in 2D and 3D environments through regulation of fibronectin domain stability. Biomaterials (2008) 1.82
Three-dimensional extracellular matrix-directed cardioprogenitor differentiation: systematic modulation of a synthetic cell-responsive PEG-hydrogel. Biomaterials (2008) 1.78
Photopolymerized hyaluronic acid-based hydrogels and interpenetrating networks. Biomaterials (2003) 1.77
Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci Transl Med (2011) 1.74
Secondary lymphedema in the mouse tail: Lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9. Microvasc Res (2006) 1.70
Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev (2012) 1.64
CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity (2005) 1.63
Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc Pathol (2003) 1.63
The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB J (2010) 1.62
Synergy between interstitial flow and VEGF directs capillary morphogenesis in vitro through a gradient amplification mechanism. Proc Natl Acad Sci U S A (2005) 1.59
Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Invest (2013) 1.57
Biologically engineered protein-graft-poly(ethylene glycol) hydrogels: a cell adhesive and plasmin-degradable biosynthetic material for tissue repair. Biomacromolecules (2002) 1.55
Controlled release nanoparticle-embedded coatings reduce the tissue reaction to neuroprostheses. J Control Release (2010) 1.54
VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep (2012) 1.51
Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. FASEB J (2007) 1.50
Cell-responsive hydrogel for encapsulation of vascular cells. Biomaterials (2009) 1.50
Biomolecular hydrogels formed and degraded via site-specific enzymatic reactions. Biomacromolecules (2007) 1.50
PEG-SS-PPS: reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery. Biomacromolecules (2007) 1.49
An agarose-based microfluidic platform with a gradient buffer for 3D chemotaxis studies. Biomed Microdevices (2009) 1.48
Synthetic extracellular matrices for in situ tissue engineering. Biotechnol Bioeng (2004) 1.48
Engineering synthetic vaccines using cues from natural immunity. Nat Mater (2013) 1.48
Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol Bioeng (2005) 1.47
Hypercholesterolemic mice exhibit lymphatic vessel dysfunction and degeneration. Am J Pathol (2009) 1.47
The effect of matrix characteristics on fibroblast proliferation in 3D gels. Biomaterials (2010) 1.46
Engineering integrin signaling for promoting embryonic stem cell self-renewal in a precisely defined niche. Biomaterials (2009) 1.45
Bovine primary chondrocyte culture in synthetic matrix metalloproteinase-sensitive poly(ethylene glycol)-based hydrogels as a scaffold for cartilage repair. Tissue Eng (2004) 1.43
A driving force for change: interstitial flow as a morphoregulator. Trends Cell Biol (2006) 1.43
Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res (2009) 1.41
Transmural flow modulates cell and fluid transport functions of lymphatic endothelium. Circ Res (2010) 1.41
Bronchial epithelial compression regulates MAP kinase signaling and HB-EGF-like growth factor expression. Am J Physiol Lung Cell Mol Physiol (2002) 1.40
RGD-grafted poly-L-lysine-graft-(polyethylene glycol) copolymers block non-specific protein adsorption while promoting cell adhesion. Biotechnol Bioeng (2003) 1.40
Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1alpha variant for local induction of angiogenesis. Proc Natl Acad Sci U S A (2006) 1.39
Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A (2011) 1.39
Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc Natl Acad Sci U S A (2013) 1.39
Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine (2010) 1.37
Dendritic cell chemotaxis in 3D under defined chemokine gradients reveals differential response to ligands CCL21 and CCL19. Proc Natl Acad Sci U S A (2011) 1.36
Engineering approaches to immunotherapy. Sci Transl Med (2012) 1.36
Characterization of lymphangiogenesis in a model of adult skin regeneration. Am J Physiol Heart Circ Physiol (2006) 1.35
Interstitial flow differentially stimulates blood and lymphatic endothelial cell morphogenesis in vitro. Microvasc Res (2004) 1.35
Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering. Biomaterials (2007) 1.34
Mechanisms of neonatal mucosal antibody protection. J Immunol (2006) 1.32
Fluid flow regulates stromal cell organization and CCL21 expression in a tissue-engineered lymph node microenvironment. J Immunol (2009) 1.30
Poly(ethylene glycol) hydrogels formed by conjugate addition with controllable swelling, degradation, and release of pharmaceutically active proteins. J Control Release (2005) 1.30
Migration dynamics of breast cancer cells in a tunable 3D interstitial flow chamber. Integr Biol (Camb) (2011) 1.28
Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science (2014) 1.27
Fibroblast alignment under interstitial fluid flow using a novel 3-D tissue culture model. Am J Physiol Heart Circ Physiol (2003) 1.27
The effect of enzymatically degradable poly(ethylene glycol) hydrogels on smooth muscle cell phenotype. Biomaterials (2007) 1.26
In situ cell manipulation through enzymatic hydrogel photopatterning. Nat Mater (2013) 1.24
Engineering the regenerative microenvironment with biomaterials. Adv Healthc Mater (2012) 1.24
An ultra-thin PDMS membrane as a bio/micro-nano interface: fabrication and characterization. Biomed Microdevices (2007) 1.23
Recombinant protein-co-PEG networks as cell-adhesive and proteolytically degradable hydrogel matrixes. Part II: biofunctional characteristics. Biomacromolecules (2006) 1.23
Regulation of lymphatic capillary regeneration by interstitial flow in skin. Am J Physiol Heart Circ Physiol (2006) 1.22
The effect of the linker on the hydrolysis rate of drug-linked ester bonds. J Control Release (2004) 1.21
Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses. Proc Natl Acad Sci U S A (2005) 1.21
Doxorubicin encapsulation and diffusional release from stable, polymeric, hydrogel nanoparticles. Eur J Pharm Sci (2006) 1.20
The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. Biomaterials (2007) 1.18
Dermal collagen and lipid deposition correlate with tissue swelling and hydraulic conductivity in murine primary lymphedema. Am J Pathol (2010) 1.18
Lymphatic drainage function and its immunological implications: from dendritic cell homing to vaccine design. Semin Immunol (2008) 1.17
Tumor cell invasion is promoted by interstitial flow-induced matrix priming by stromal fibroblasts. Cancer Res (2011) 1.16
Impaired humoral immunity and tolerance in K14-VEGFR-3-Ig mice that lack dermal lymphatic drainage. J Immunol (2012) 1.15
Autologous morphogen gradients by subtle interstitial flow and matrix interactions. Biophys J (2006) 1.13
Recombinant protein-co-PEG networks as cell-adhesive and proteolytically degradable hydrogel matrixes. Part I: Development and physicochemical characteristics. Biomacromolecules (2005) 1.13
Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials (2013) 1.13
Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS One (2013) 1.12
An in vitro airway wall model of remodeling. Am J Physiol Lung Cell Mol Physiol (2003) 1.11
Physiological 3D tissue model of the airway wall and mucosa. Nat Protoc (2006) 1.10
Bond-detach lithography: a method for micro/nanolithography by precision PDMS patterning. Small (2007) 1.10